|
|
早期非小细胞肺癌综合治疗的进展
|
Abstract:
新辅助治疗和手术切除是目前治疗非小细胞肺癌(NSCLC)的主要有效手段，随着低剂量螺旋CT的广泛应用，越来越多的早期非小细胞肺癌被发现，这为早期肺癌的治疗提供了更多的可能性。解剖性肺叶切除术是目前治疗非小细胞肺癌的标准术式，但随着影像学技术的进步以及临床大夫对于肺部解剖的不断探索，目前已有部分研究显示，早期非小细胞肺癌患者行肺段切除术是安全可行的。但是由于肺段切除术的切除范围要小于肺叶切除术，这可能使得术后复发或者转移的风险增高。随着新辅助治疗的不断发展，已经有研究证实，新辅助治疗可以降低肺癌术后复发和转移的风险。但是，最终能给病人带来多大的生存获益仍需长期的随访和大量的临床试验来验证。
Surgical resection is the main effective means for the treatment of non-small cell lung cancer, and with the wide application of low-dose spiral CT, more and more early non-small cell lung cancer has been found, which provides more possibilities for the treatment of early lung cancer. Anatomical lobectomy is currently the standard surgical procedure for the treatment of non-small cell lung cancer. However, with the progress of imaging technology and the continuous exploration of lung anatomy by clinicians, some studies have shown that segmental resection is safe and feasible for patients with early stage non-small cell lung cancer. However, since segmental resection is less extensive than lobectomy, it may increase the risk of postoperative recurrence or metastasis. With the continuous development of neoadjuvant therapy, studies have confirmed that neoadjuvant therapy can reduce the risk of postoperative recurrence and metastasis of lung cancer. However, long-term follow-up and extensive clinical trials are needed to determine the ultimate survival benefit.
| [1] | Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [2] | Stanley, K. and Stjernsward, J. (1989) Lung Cancer—A Worldwide Health Problem. Chest, 96, 1S-5S.
https://doi.org/10.1378/chest.96.1_Supplement.1S |
| [3] | Zheng, R., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9.
https://doi.org/10.1016/j.jncc.2022.02.002 |
| [4] | 国家卫生健康委办公厅. 原发性肺癌诊疗指南(2022年版) [J]. 协和医学杂志, 2022, 13(4): 549-570. |
| [5] | 毕磊, 等. 电视胸腔镜肺叶切除术治疗老年周围型非小细胞肺癌的疗效[J]. 医学信息, 2021, 34(7): 6-9+14. |
| [6] | Paz-Ares, L., et al. (2019) LBA3 Nivolumab (NIVO) + Platinum-Doublet Chemotherapy (Chemo) vs Chemo as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (aNSCLC): CheckMate 227—Part 2 Final Analysis. Annals of Oncology, 30, xi67-xi68. https://doi.org/10.1093/annonc/mdz453.004 |
| [7] | Handa, Y., et al. (2019) Surgical Outcomes of Complex versus Simple Segmentectomy for Stage I Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery, 107, 1032-1039. https://doi.org/10.1016/j.athoracsur.2018.11.018 |
| [8] | Ginsberg, R.J. and Rubinstein, L.V. (1995) Randomized Trial of Lobectomy versus Limited Resection for T1 N0 Non-Small Cell Lung Cancer. Lung Cancer Study Group. The Annals of Thoracic Surgery, 60, 615-622.
https://doi.org/10.1016/0003-4975(95)00537-U |
| [9] | 王艳菊, 等. 高分辨薄层CT在早期肺腺癌诊断筛查中的应用价值[J]. 临床与病理杂志, 2021, 41(3): 549-553. |
| [10] | 申江峰, 等. 三维重建指导下解剖性肺段切除43例分析[J]. 中国现代医生, 2020, 58(13): 57-59, 71, 封3页. |
| [11] | Saji, H., Okada, M., et al. (2022) Segmentectomy versus Lobectomy in Small-Sized Peripheral Non-Small-Cell Lung Cancer (JCOG0802/WJOG4607L): A Multicentre, Open-Label, Phase 3, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 399, 1607-1617. https://doi.org/10.1016/S0140-6736(21)02333-3 |
| [12] | Suzuki, K., et al. (2022) A Single-Arm Study of Sublobar Resection for Ground-Glass Opacity Dominant Peripheral Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 163, 289-301.e2.
https://doi.org/10.1016/j.jtcvs.2020.09.146 |
| [13] | 中华医学会肿瘤学分会与中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022版) [J]. 中华肿瘤杂志, 2022, 44(6): 457-490. |
| [14] | Rd, N., et al. (2019) Lung Cancer. BMJ (Clinical Research ed.), 365, l1725. https://doi.org/10.1136/bmj.l1725 |
| [15] | Ellis, P.M. and Vandermeer, R. (2011) Delays in the Diagnosis of Lung Cancer. Journal of Thoracic Disease, 3, 183-188. |
| [16] | Henschke, C.I., et al. (1999) Early Lung Cancer Action Project: Overall Design and Findings from Baseline Screening. The Lancet, 354, 99-105. https://doi.org/10.1016/S0140-6736(99)06093-6 |
| [17] | Henschke, C.I., et al. (2001) Early Lung Cancer Action Project: Initial Findings on Repeat Screenings. Cancer, 92, 153-159. https://doi.org/10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S |
| [18] | 赵殿辉, 庄悦新. HRCT诊断周围型小肺癌的价值[J]. 滨州医学院学报, 1998(1): 19-20. |
| [19] | 王宪. 高分辨CT在肺腺癌诊断中的应用分析[J]. 世界复合医学, 2022, 8(3): 49-52. |
| [20] | Nakazawa, S., et al. (2018) VATS Segmentectomy: Past, Present, and Future. General Thoracic and Cardiovascular Surgery, 66, 81-90. https://doi.org/10.1007/s11748-017-0878-6 |
| [21] | Cao, C., et al. (2015) Could Less Be More?—A Systematic Re-view and Meta-Analysis of Sublobar Resections versus Lobectomy for Non-Small Cell Lung Cancer According to Pa-tient Selection. Lung Cancer, 89, 121-132.
https://doi.org/10.1016/j.lungcan.2015.05.010 |
| [22] | Bedat, B., et al. (2019) Comparison of Postoperative Compli-cations between Segmentectomy and Lobectomy by Video-Assisted Thoracic Surgery: A Multicenter Study. Journal of Cardiothoracic Surgery, 14, 189.
https://doi.org/10.1186/s13019-019-1021-9 |
| [23] | Blasberg, J.D., Pass, H.I. and Donington, J.S. (2010) Sublobar Resection: A Movement from the Lung Cancer Study Group. Journal of Thoracic Oncology, 5, 1583-1593. https://doi.org/10.1097/JTO.0b013e3181e77604 |
| [24] | Zhong, C., et al. (2012) Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer. The Annals of Thoracic Surgery, 94, 362-367. https://doi.org/10.1016/j.athoracsur.2012.04.047 |
| [25] | Lin, Y., et al. (2016) Comparison of Treatment Outcomes between Single-Port Video-Assisted Thoracoscopic Anatomic Segmentectomy and Lobectomy for Non-Small Cell Lung Cancer of Early-Stage: A Retrospective Observational Study. Journal of Thoracic Disease, 8, 1290-1296. https://doi.org/10.21037/jtd.2016.04.65 |
| [26] | Zhao, X., et al. (2013) Segmentectomy as a Safe and Equally Effective Surgical Option under Complete Video-Assisted Thoracic Surgery for Patients of Stage I Non-Small Cell Lung Cancer. Journal of Cardiothoracic Surgery, 8, 116. https://doi.org/10.1186/1749-8090-8-116 |
| [27] | Molina, J.R., et al. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594. https://doi.org/10.1016/S0025-6196(11)60735-0 |
| [28] | Winton, T., et al. (2005) Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 352, 2589-2597. https://doi.org/10.1056/NEJMoa043623 |
| [29] | Pignon, J.P., et al. (2008) Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26, 3552-3559. https://doi.org/10.1200/JCO.2007.13.9030 |
| [30] | Arriagada, R., Dunant, A., et al. (2004) Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 350, 351-360.
https://doi.org/10.1056/NEJMoa031644 |
| [31] | Cloughesy, T.F., et al. (2019) Neoadjuvant Anti-PD-1 Immuno-therapy Promotes a Survival Benefit with Intratumoral and Systemic Immune Responses in Recurrent Glioblastoma. Nature Medicine, 25, 477-486.
https://doi.org/10.1038/s41591-018-0337-7 |
| [32] | Forde, P.M., et al. (2022) Neoadjuvant Nivolumab plus Chemo-therapy in Resectable Lung Cancer. The New England Journal of Medicine, 386, 1973-1985. https://doi.org/10.1056/NEJMoa2202170 |
| [33] | Alifu, N., et al. (2022) Correction to “Single-Molecular Near-Infrared-II Theranostic Systems: Ultrastable Aggregation-Induced Emission Nanoparticles for Long-Term Tracing and Efficient Photothermal Therapy”. ACS Nano, 16, 9961-9961. https://doi.org/10.1021/acsnano.2c04138 |
